Is CJC-1295 DAC FDA approved?

CJC-1295 DAC is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is IGF-1 FDA approved?

IGF-1 is FDA approved (FDA status current as of 2005-08-30). This regulatory status is provided for research and educational context only.

How is CJC-1295 DAC administered in research settings?

In research settings, CJC-1295 DAC is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is IGF-1 administered in research settings?

In research settings, IGF-1 is typically administered via the subcutaneous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›CJC-1295 DAC vs IGF-1

Peptide Comparison

CJC-1295 DAC vs IGF-1

Name: CJC-1295 DAC vs IGF-1 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are GH / IGF Axis peptides.

CJC-1295 DAC

CJC-1295 with DAC

Fat LossNot EvaluatedResearch Only

Half-life: 6–8 days

1 providers listed

Full CJC-1295 DAC profile →

IGF-1

Insulin-like Growth Factor 1

PerformanceFDA ApprovedResearch Only

21 providers listed

Full IGF-1 profile →

Bottom line

IGF-1 is FDA-approved, while CJC-1295 DAC is not evaluated — the clearest structural difference between them.

Quick Verdict

CJC-1295 DAC

Half-life

6–8 days

IGF-1

Half-life

—

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	CJC-1295 DAC
Further along in FDA review	IGF-1
Lower typical price per mg	CJC-1295 DAC
More provider options (1 vs 21)	IGF-1

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

CJC-1295 DAC

IGF-1

Mechanism Family

GH / IGF Axis

Half-life

6–8 days

—

FDA Status

not evaluated

approved

Admin Routes

subcutaneous

subcutaneous, intramuscular

Availability

Research Only

Providers

1 listed

21 listed

FDA Update

—

Aug 2005

Avail. Notes

Long-acting GHRH analog with a Drug Affinity Complex (DAC) modification. No FDA approval. Not on the FDA 503A bulks list. WADA-prohibited as a growth hormone releasing factor. Sold as a research chemical only.

FDA-approved: Increlex (mecasermin, recombinant human IGF-1), Drugs@FDA application 021839.

Research Evidence

CJC-1295 DAC

RCT · 1 key study · dated evidence base — most recent 2006

IGF-1

Cohort study · 1 key study · most recent 2026

Research Citations

CJC-1295 DAC

RCT2006 · Journal of Clinical Endocrinology and Metabolism

Effects of a single injection of CJC-1295, a long-acting growth hormone-releasing hormone analog, in healthy…

IGF-1

Cohort2026 · Pituitary

Speckle-tracking echocardiography reveals the synergistic impact of GH/IGF-1 excess and metabolic dysregulati…

About CJC-1295 DAC

CJC-1295 DAC is a GHRH analog carrying a Drug Affinity Complex (DAC) modification that binds covalently to circulating albumin, greatly extending its plasma half-life relative to unmodified or short-acting GHRH analogs. Through this albumin binding it acts as a long-lasting agonist at pituitary GHRH receptors, associated in research with sustained growth hormone and downstream IGF-1 elevation. This contrasts with the non-DAC form (Mod GRF 1-29), whose action is measured in minutes rather than days.

Research Areas

GH and IGF-1 elevation studied in a single-dose human PK trialsustained GHRH-receptor agonism via albumin bindingextended plasma half-life relative to short-acting GHRH analogsbody-composition and GH-axis research contextssubcutaneous administration in published research

About IGF-1

Binds IGF-1R with high affinity, activating PI3K/Akt and MAPK pathways promoting protein synthesis, satellite cell activation, and glucose uptake. Much shorter half-life (~15 min) than the LR3 analog (~20-30 hr) due to binding protein interactions.

Research Areas

muscle growthrecoveryfat metabolismtissue repairGH axis

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

CJC-1295 DAC

Warnings & Cautions

Active malignancy — caution (GH/IGF-1 is mitogenic)Pregnancy — cautionKnown hypersensitivityGlucose intolerance / insulin resistance

Class-based (investigational)

Suggested Monitoring

IGF-1Fasting glucoseHbA1cInsulin

Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.

Regulatory Notes

global — WADA

This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.

source

IGF-1

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Price (per mg)

CJC-1295 DAC

$10.63/mg

$9.74 – $15.25 range

20 vendors

View price index →Find providers →

IGF-1

$54.33/mg

$29.30 – $73.44 range

8 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

CJC-1295 DAC

1 listed

Browse directory →

Providers offering

IGF-1

21 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). CJC-1295 DAC vs IGF-1 — Per-mg Price Comparison. Retrieved September 12, 2026, from https://peptidebase.io/peptides/compare/cjc-1295-dac/igf-1

https://peptidebase.io/peptides/compare/cjc-1295-dac/igf-1 Methodology License Download JSON Download CSV